Leveraging Technology to Cut Through the REMS Confusion

The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.

Download White Paper

You may also like:

Blog Post

Blockchain, the distributed ledger technology, continues to expand in the financial industry, but we haven’t yet examined its full potential to transform the healthcare industry. Healthcare, and the pharmacy industry specific...

View Blog Post
Blog Post

Pain management is an area of concern for many healthcare professionals, and not just because it’s so prevalent in the national news cycle. In her article “To tre...

View Blog Post
Blog Post

Because of the concern about prescription opioid abuse and the growing numbers of dependent opioid users switching to heroin, it is of interest to ascertain the rate and incidence of such transition. Accord...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up